Press releases

After 30 successful years with Boston Scientific, Dan will work closely with CFO successor Jon Monson to ensure a smooth transition.

"We delivered an exceptional quarter to start the year,” said Mike Mahoney, chairman and CEO, Boston Scientific.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2025. Learn how to tune in.

Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension

Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has completed a public...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.

Boston Scientific will participate in the upcoming healthcare conference in Marach 2025.

"2024 was one of the best years in the history of Boston Scientific,” said Mike Mahoney, chairman and CEO.

Data sets for two clinical trials show positive results for both FARAPULSE pulsed field ablation and the WATCHMAN device for treating Afib.

“Miriam has a broad base of HR experience with a demonstrated ability to lead large-scale business transformations,” said Mike Mahoney, Boston Scientific CEO.